Observational Study of Quality of Live in Patients With Metastatic Pancreatic Cancer
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2019-01-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 120
- Registration Number
- NCT02342847
- Locations
- 🇪🇸
Hospital Universitario Burgos, Burgos, Castilla Y León, Spain
🇪🇸Complejo Asistencial León, León, Castilla Y León, Spain
🇪🇸Germans Trias i Pujol, Badalona, Cataluña, Spain
Observational Study of Lenalidomide in Subjects With Mantle Cell Lymphoma Who Failed Ibrutinib Treatment
- Conditions
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Celgene
- Target Recruit Count
- 30
- Registration Number
- NCT02341781
- Locations
- 🇺🇸
University of Miami and Sylvester Comprehensive Cancer, Miami, Florida, United States
🇺🇸University of Michigan Comprehensive Cancer Center Division of Hematology Oncology, Ann Arbor, Michigan, United States
🇮🇹Azienda Ospedaliero Universitaria Di Bologna - Policlinico S.Orsola Malpighi, Bologna, Emilia-Romagna, Italy
Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab
- First Posted Date
- 2015-01-05
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 121
- Registration Number
- NCT02330562
- Locations
- 🇺🇸
John Wayne Cancer Institute, Santa Monica, California, United States
🇺🇸University of Californai, Irvine, Orange, California, United States
🇨🇦Princess Margaret Hospital, Medical Oncology, Toronto, Ontario, Canada
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 12
- Registration Number
- NCT02323906
- Locations
- 🇺🇸
University of Florida College of Med, Gainesville, Florida, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 26
- Registration Number
- NCT02321644
- Locations
- 🇺🇸
Covance-Daytona Beach, Daytona Beach, Florida, United States
🇺🇸TKL Research, Fair Lawn, New Jersey, United States
Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 19
- Registration Number
- NCT02313012
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Inflammatory Bowel Disease Center, Los Angeles, California, United States
🇺🇸Smilow Cancer Center, New Haven, Connecticut, United States
🇺🇸Levine Cancer Institute, Charlotte, North Carolina, United States
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-12-05
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- Celgene
- Target Recruit Count
- 114
- Registration Number
- NCT02309177
- Locations
- 🇺🇸
Northwestern University-NMDTI, Chicago, Illinois, United States
🇺🇸Dana-Farber / Harvard Cancer Institute, Boston, Massachusetts, United States
🇺🇸Ohio State Medical Center, Columbus, Ohio, United States
Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)
- Conditions
- Interventions
- First Posted Date
- 2014-11-25
- Last Posted Date
- 2019-03-20
- Lead Sponsor
- Celgene
- Target Recruit Count
- 107
- Registration Number
- NCT02301143
- Locations
- 🇺🇸
University of Massachusetts, Worcester, Massachusetts, United States
🇺🇸Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸Tufts - New England Medical Center, Boston, Massachusetts, United States
Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)
- Conditions
- Interventions
- First Posted Date
- 2014-11-19
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Celgene
- Target Recruit Count
- 1346
- Registration Number
- NCT02294058
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Neurological Research Institute Inc, Columbus, Ohio, United States
🇺🇸The Polyclinic, Seattle, Washington, United States
Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Celgene
- Target Recruit Count
- 40
- Registration Number
- NCT02289456
- Locations
- 🇺🇸
University Cancer Institute, Boynton Beach, Florida, United States
🇺🇸Ochsner Clinic Nephrology, New Orleans, Louisiana, United States
🇺🇸University of RochesterJames P. Wilmont Cancer Center, Rochester, New York, United States